Skip to content

Home Search Authors Pakistan News Saved

SciRah

SciRah does not host or store research papers. Results come live from free, official scholarly APIs, and every paper links back to its original source.

Data sources

OpenAlex
Semantic Scholar
Crossref
CORE
arXiv
PubMed

Privacy policy Terms of service

H. Woerle · SciRah

Researcher profile · Semantic Scholar

H. Woerle

Share profile

H. Woerle — researcher profile on SciRah

h-index: 78
Works: 223
Citations: 29K

Most-cited papers

Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes.
B. Zinman, C. Wanner, J. Lachin, D. Fitchett +8 more
2015New England Journal of Medicine6,082 citations Open access
Semantic Scholar
Renal Hemodynamic Effect of Sodium-Glucose Cotransporter 2 Inhibition in Patients With Type 1 Diabetes Mellitus
D. Cherney, B. Perkins, Nima Soleymanlou, M. Maione +7 more
2014Circulation1,203 citations Open access
Semantic Scholar
Effect of Linagliptin vs Placebo on Major Cardiovascular Events in Adults With Type 2 Diabetes and High Cardiovascular and Renal Risk: The CARMELINA Randomized Clinical Trial
J. Rosenstock, V. Perkovic, O. Johansen, M. Cooper +15 more
2019Journal of the American Medical Association (JAMA)987 citations Open access
Semantic Scholar
Heart failure outcomes with empagliflozin in patients with type 2 diabetes at high cardiovascular risk: results of the EMPA-REG OUTCOME® trial
D. Fitchett, B. Zinman, C. Wanner, J. Lachin +6 more
2016European Heart Journal911 citations Open access
Semantic Scholar
Effect of Linagliptin vs Glimepiride on Major Adverse Cardiovascular Outcomes in Patients With Type 2 Diabetes: The CAROLINA Randomized Clinical Trial.
J. Rosenstock, S. Kahn, O. Johansen, B. Zinman +11 more
2019Journal of the American Medical Association (JAMA)532 citations Open access
Semantic Scholar
Efficacy and safety of empagliflozin added to existing antidiabetes treatment in patients with type 2 diabetes and chronic kidney disease: a randomised, double-blind, placebo-controlled trial.
A. Barnett, A. Mithal, Jenny Manassie, Russell Jones +3 more
2014The Lancet Diabetes and Endocrinology516 citations
Semantic Scholar
Effects of empagliflozin on blood pressure and markers of arterial stiffness and vascular resistance in patients with type 2 diabetes
R. Chilton, I. Tikkanen, C. Cannon, S. Crowe +3 more
2015Diabetes, obesity and metabolism450 citations Open access
Semantic Scholar
Empagliflozin and Clinical Outcomes in Patients With Type 2 Diabetes Mellitus, Established Cardiovascular Disease, and Chronic Kidney Disease
C. Wanner, J. Lachin, S. Inzucchi, D. Fitchett +6 more
2018Circulation386 citations Open access
Semantic Scholar
SGLT-2 inhibitors and cardiovascular risk: Proposed pathways and review of ongoing outcome trials
S. Inzucchi, B. Zinman, C. Wanner, R. Ferrari +6 more
2015Diabetes & vascular disease research383 citations Open access
Semantic Scholar
The effect of empagliflozin on arterial stiffness and heart rate variability in subjects with uncomplicated type 1 diabetes mellitus
D. Cherney, B. Perkins, Nima Soleymanlou, R. Har +5 more
2014Cardiovascular Diabetology376 citations Open access
Semantic Scholar
Combination of Empagliflozin and Linagliptin as Second-Line Therapy in Subjects With Type 2 Diabetes Inadequately Controlled on Metformin
R. DeFronzo, A. Lewin, Sanjay R. Patel, Da-Cheng Liu +3 more
2015Diabetes Care295 citations
Semantic Scholar
Impact of empagliflozin added on to basal insulin in type 2 diabetes inadequately controlled on basal insulin: a 78‐week randomized, double‐blind, placebo‐controlled trial
J. Rosenstock, A. Jelaska, C. Zeller, G. Kim +2 more
2015Diabetes, obesity and metabolism239 citations Open access
Semantic Scholar
Pooled analysis of Phase III trials indicate contrasting influences of renal function on blood pressure, body weight, and HbA1c reductions with empagliflozin.
D. Cherney, M. Cooper, I. Tikkanen, E. Pfarr +4 more
2018Kidney International227 citations Open access
Semantic Scholar
Effects of empagliflozin on risk for cardiovascular death and heart failure hospitalization across the spectrum of heart failure risk in the EMPA-REG OUTCOME® trial
D. Fitchett, J. Butler, P. van de Borne, B. Zinman +7 more
2018European Heart Journal225 citations Open access
Semantic Scholar
Design and baseline characteristics of the CARdiovascular Outcome Trial of LINAgliptin Versus Glimepiride in Type 2 Diabetes (CAROLINA®)
N. Marx, J. Rosenstock, S. Kahn, B. Zinman +9 more
2015Diabetes & vascular disease research224 citations Open access
Semantic Scholar
Initial Combination of Empagliflozin and Linagliptin in Subjects With Type 2 Diabetes
A. Lewin, R. DeFronzo, Sanjay R. Patel, Da-Cheng Liu +3 more
2015Diabetes Care186 citations
Semantic Scholar
The effect of sodium glucose cotransporter 2 inhibition with empagliflozin on microalbuminuria and macroalbuminuria in patients with type 2 diabetes
D. Cherney, S. Lund, B. Perkins, P. Groop +5 more
2016Diabetologia177 citations Open access
Semantic Scholar
Empagliflozin and Kidney Function Decline in Patients with Type 2 Diabetes: A Slope Analysis from the EMPA-REG OUTCOME Trial.
C. Wanner, H. Heerspink, B. Zinman, S. Inzucchi +7 more
2018Journal of the American Society of Nephrology173 citations Open access
Semantic Scholar
Empagliflozin as adjunct to insulin in patients with type 1 diabetes: a 4‐week, randomized, placebo‐controlled trial (EASE‐1)
T. Pieber, S. Famulla, Jens Eilbracht, Jessica Cescutti +5 more
2015Diabetes, obesity and metabolism164 citations Open access
Semantic Scholar
Empagliflozin reduces body weight and indices of adipose distribution in patients with type 2 diabetes mellitus
I. Neeland, Darren K Mcguire, R. Chilton, S. Crowe +4 more
2016Diabetes & vascular disease research162 citations Open access
Semantic Scholar
Characterisation of glomerular haemodynamic responses to SGLT2 inhibition in patients with type 1 diabetes and renal hyperfiltration
M. Škrtić, Gary K. Yang, B. Perkins, Nima Soleymanlou +8 more
2014Diabetologia154 citations Open access
Semantic Scholar
Empagliflozin and Cardiovascular Outcomes in Asian Patients With Type 2 Diabetes and Established Cardiovascular Disease - Results From EMPA-REG OUTCOME®.
K. Kaku, Jisoo Lee, M. Mattheus, S. Kaspers +2 more
2017Circulation Journal119 citations Open access
Semantic Scholar
Empagliflozin and Cerebrovascular Events in Patients With Type 2 Diabetes Mellitus at High Cardiovascular Risk
B. Zinman, S. Inzucchi, J. Lachin, C. Wanner +8 more
2017Stroke118 citations Open access
Semantic Scholar
Pharmacokinetics, pharmacodynamics and safety of empagliflozin, a sodium glucose cotransporter 2 (SGLT2) inhibitor, in subjects with renal impairment
S. Macha, M. Mattheus, A. Halabi, Sabine Pinnetti +2 more
2014Diabetes, obesity and metabolism117 citations
Semantic Scholar
Empagliflozin as Add-on Therapy to Pioglitazone With or Without Metformin in Patients With Type 2 Diabetes Mellitus.
C. Kovacs, V. Seshiah, L. Merker, A. Christiansen +6 more
2015Clinical Therapeutics114 citations
Semantic Scholar
Safety, tolerability and effects on cardiometabolic risk factors of empagliflozin monotherapy in drug-naïve patients with type 2 diabetes: a double-blind extension of a Phase III randomized controlled trial
M. Roden, L. Merker, A. Christiansen, Flavien Roux +5 more
2015Cardiovascular Diabetology113 citations Open access
Semantic Scholar
Impact of Empagliflozin on Blood Pressure in Patients With Type 2 Diabetes Mellitus and Hypertension by Background Antihypertensive Medication
G. Mancia, C. Cannon, I. Tikkanen, C. Zeller +4 more
2016HYPERTENSION108 citations Open access
Semantic Scholar
Kidney Disease End Points in a Pooled Analysis of Individual Patient-Level Data From a Large Clinical Trials Program of the Dipeptidyl Peptidase 4 Inhibitor Linagliptin in Type 2 Diabetes.
M. Cooper, V. Perkovic, J. McGill, P. Groop +5 more
2015American Journal of Kidney Diseases106 citations Open access
Semantic Scholar
Initial Combination of Empagliflozin and Metformin in Patients With Type 2 Diabetes
S. Hadjadj, J. Rosenstock, T. Meinicke, H. Woerle +1 more
2016Diabetes Care104 citations Open access
Semantic Scholar
The effect of empagliflozin on muscle sympathetic nerve activity in patients with type II diabetes mellitus.
J. Jordan, J. Tank, K. Heusser, T. Heise +7 more
2017Journal of the American Society of Hypertension : JASH88 citations
Semantic Scholar
Safety and Tolerability of Empagliflozin in Patients with Type 2 Diabetes.
Sven Kohler, Afshin Salsali, S. Hantel, S. Kaspers +3 more
2016Clinical Therapeutics88 citations Open access
Semantic Scholar
Empagliflozin as add‐on to metformin in people with Type 2 diabetes
L. Merker, H. Häring, A. Christiansen, Flavien Roux +5 more
2015Diabetic Medicine87 citations
Semantic Scholar
Pharmacodynamic Effects of Single and Multiple Doses of Empagliflozin in Patients With Type 2 Diabetes.
T. Heise, J. Jordan, C. Wanner, M. Heer +5 more
2016Clinical Therapeutics85 citations
Semantic Scholar
Rationale, design, and baseline characteristics of the CArdiovascular safety and Renal Microvascular outcomE study with LINAgliptin (CARMELINA®): a randomized, double-blind, placebo-controlled clinical trial in patients with type 2 diabetes and high cardio-renal risk
J. Rosenstock, V. Perkovic, J. Alexander, M. Cooper +13 more
2018Cardiovascular Diabetology80 citations Open access
Semantic Scholar
Cardiovascular safety of linagliptin in type 2 diabetes: a comprehensive patient-level pooled analysis of prospectively adjudicated cardiovascular events
J. Rosenstock, N. Marx, D. Neubacher, T. Seck +3 more
2015Cardiovascular Diabetology78 citations Open access
Semantic Scholar
Empagliflozin as add-on to metformin plus sulphonylurea in patients with type 2 diabetes.
H. Haering, L. Merker, A. Christiansen, Flavien Roux +5 more
2015Diabetes Research and Clinical Practice78 citations
Semantic Scholar
Composite Primary End Points in Cardiovascular Outcomes Trials Involving Type 2 Diabetes Patients: Should Unstable Angina Be Included in the Primary End Point?
N. Marx, D. McGuire, V. Perkovic, H. Woerle +4 more
2017Diabetes Care68 citations Open access
Semantic Scholar
Analysis of Fractures in Patients With Type 2 Diabetes Treated With Empagliflozin in Pooled Data From Placebo-Controlled Trials and a Head-to-Head Study Versus Glimepiride
Sven Kohler, S. Kaspers, Afshin Salsali, C. Zeller +1 more
2018Diabetes Care57 citations
Semantic Scholar
Acute Pharmacodynamic Effects of Empagliflozin With and Without Diuretic Agents in Patients With Type 2 Diabetes Mellitus.
T. Heise, J. Jordan, C. Wanner, M. Heer +5 more
2016Clinical Therapeutics57 citations
Semantic Scholar
Treatment With the Dipeptidyl Peptidase-4 Inhibitor Linagliptin or Placebo Followed by Glimepiride in Patients With Type 2 Diabetes With Moderate to Severe Renal Impairment: A 52-Week, Randomized, Double-Blind Clinical Trial
M. Laakso, J. Rosenstock, P. Groop, A. Barnett +6 more
2015Diabetes Care57 citations Open access
Semantic Scholar
Long‐term treatment with empagliflozin as add‐on to oral antidiabetes therapy in Japanese patients with type 2 diabetes mellitus
E. Araki, Y. Tanizawa, Yuko Tanaka, Atsushi Taniguchi +5 more
2015Diabetes, obesity and metabolism57 citations
Semantic Scholar
Influence of TCF7L2 gene variants on the therapeutic response to the dipeptidylpeptidase-4 inhibitor linagliptin
H. Zimdahl, C. Ittrich, Ulrike Graefe-Mody, B. Boehm +3 more
2014Diabetologia57 citations Open access
Semantic Scholar
Efficacy and safety of empagliflozin twice daily versus once daily in patients with type 2 diabetes inadequately controlled on metformin: a 16‐week, randomized, placebo‐controlled trial
S. Ross, C. Thamer, Jessica Cescutti, T. Meinicke +2 more
2015Diabetes, obesity and metabolism50 citations
Semantic Scholar
Glucose Exposure and Variability with Empagliflozin as Adjunct to Insulin in Patients with Type 1 Diabetes: Continuous Glucose Monitoring Data from a 4-Week, Randomized, Placebo-Controlled Trial (EASE-1)
S. Famulla, T. Pieber, Jens Eilbracht, D. Neubacher +4 more
2017Diabetes Technology & Therapeutics49 citations
Semantic Scholar
Efficacy and Safety of Empagliflozin Monotherapy for 52 Weeks in Japanese Patients with Type 2 Diabetes: A Randomized, Double-Blind, Parallel-Group Study
T. Kadowaki, M. Haneda, N. Inagaki, Y. Terauchi +5 more
2015Advances in Therapy48 citations
Semantic Scholar
Linagliptin improved glycaemic control without weight gain or hypoglycaemia in patients with Type 2 diabetes inadequately controlled by a combination of metformin and pioglitazone: a 24-week randomized, double-blind study
M. Bajaj, R. Gilman, Sanjay Patel, J. Kempthorne-Rawson +2 more
2014Diabetic Medicine48 citations Open access
Semantic Scholar
Influence of common polymorphisms in the SLC5A2 gene on metabolic traits in subjects at increased risk of diabetes and on response to empagliflozin treatment in patients with diabetes
H. Zimdahl, A. Haupt, M. Brendel, L. Bour +6 more
2017Pharmacogenetics & Genomics45 citations
Semantic Scholar
Impact of empagliflozin on blood pressure in dipper and non‐dipper patients with type 2 diabetes mellitus and hypertension
R. Chilton, I. Tikkanen, U. Hehnke, H. Woerle +1 more
2017Diabetes, obesity and metabolism44 citations
Semantic Scholar
Cardiovascular safety of empagliflozin in patients with type 2 diabetes: a meta‐analysis of data from randomized placebo‐controlled trials
Afshin Salsali, G. Kim, H. Woerle, Uli C. Broedl +1 more
2016Diabetes, obesity and metabolism44 citations Open access
Semantic Scholar
Dipeptidyl peptidase-4 inhibition with linagliptin and effects on hyperglycaemia and albuminuria in patients with type 2 diabetes and renal dysfunction: Rationale and design of the MARLINA–T2D™ trial
P. Groop, M. Cooper, V. Perkovic, K. Sharma +7 more
2015Diabetes & vascular disease research43 citations Open access
Semantic Scholar

Frequent co-authors

Invite them to SciRah by sharing their profile.

Uli C. Broedl×36
Invite
Uli C. Broedl — researcher profile on SciRah
O. Johansen×18
Invite
O. Johansen — researcher profile on SciRah
C. Wanner×13
Invite
C. Wanner — researcher profile on SciRah
M. von Eynatten×13
Invite
M. von Eynatten — researcher profile on SciRah

×12

Invite

M. Mattheus — researcher profile on SciRah

Invite

B. Zinman — researcher profile on SciRah

J. Rosenstock×10

Invite

J. Rosenstock — researcher profile on SciRah

Afshin Salsali×10

Invite

Afshin Salsali — researcher profile on SciRah

Invite

S. Hantel — researcher profile on SciRah

Invite

S. Inzucchi — researcher profile on SciRah

Invite

J. George — researcher profile on SciRah

Invite

J. Lachin — researcher profile on SciRah